Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Haddock

Showing results (261-270 of 268) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 268 results.
Advances in Radiation Oncology|June 16, 2018
Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704William F Regine, Kathryn Winter, Ross A Abrams, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2014
Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancerAkila N Viswanathan, Beth Erickson, David K Gaffney, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
The Oncologist|March 13, 2020
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704Marsha Reyngold, Kathryn A Winter, William F Regine, et al.
Radiation Oncology (London, England)|October 23, 2012
The clinical case for proton beam therapyRobert L Foote, Scott L Stafford, Ivy A Petersen, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.
JAMA Network Open|April 21, 2023
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical TrialsChristopher L Hallemeier, Jennifer Moughan, Michael G Haddock, et al.
Cancers|March 29, 2023
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and DesignBradford S Hoppe, Ivy A Petersen, Benjamin K Wilke, et al.
Pageof 27

Showing results (261-270 of 268) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 268 results.
Advances in Radiation Oncology|June 16, 2018
Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704William F Regine, Kathryn Winter, Ross A Abrams, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2014
Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancerAkila N Viswanathan, Beth Erickson, David K Gaffney, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
The Oncologist|March 13, 2020
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704Marsha Reyngold, Kathryn A Winter, William F Regine, et al.
Radiation Oncology (London, England)|October 23, 2012
The clinical case for proton beam therapyRobert L Foote, Scott L Stafford, Ivy A Petersen, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapyHunter C Gits, Amy H Tang, William S Harmsen, et al.
JAMA Network Open|April 21, 2023
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical TrialsChristopher L Hallemeier, Jennifer Moughan, Michael G Haddock, et al.
Cancers|March 29, 2023
Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and DesignBradford S Hoppe, Ivy A Petersen, Benjamin K Wilke, et al.
Pageof 27